Status:
UNKNOWN
Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC
Lead Sponsor:
Gachon University Gil Medical Center
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To determine whether in docetaxel pretreated advanced NSCLC patients with favorable clinical parameter(s) gefitinib can produce different outcomes from patients without favorable clinical parameter tr...
Detailed Description
It has been suggested that some clinical parameters, including women, no smoking history and a histologic diagnosis of adenocarcinoma, are associated with favorable outcomes of gefitinib therapy. We w...
Eligibility Criteria
Inclusion
- aged 75 years or less
- histologically or cytologically confirmed non-small cell lung cancer
- advanced, metastatic or recurrent
- ECOG performance status 0 to 2
- one prior palliative chemotherapy including docetaxel
- measurable or evaluable indicator lesion(s)
- normal marrow, hepatic and renal function
- provision of written informed consent
Exclusion
- active infection and/or severe comorbidities
- pregnant or breastfed women
- active CNS metastasis
- active bleeding in GI tract or elsewhere
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00319800
Start Date
February 1 2006
End Date
March 1 2007
Last Update
March 12 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gachon University Gil Medical Center
Incheon, South Korea, 405 760